A single white tablet and an empty prescription blister pack resting on a plain grey surface beside a closed medicine information leaflet
    HomeBlogWeighing Up Finasteride After the 2026 MHRA Safety Warning

    Weighing Up Finasteride After the 2026 MHRA Safety Warning

    5 October 2026 8 min read

    The MHRA strengthened its safety warnings for finasteride and dutasteride in May 2026. Here's what actually changed, what it doesn't mean, and where non-drug thinning hair options fit in.

    If you take finasteride for hair loss, or you're thinking about starting it, you've probably seen the headlines. The short version is this: in May 2026 the MHRA strengthened the safety information for finasteride and added a new precautionary warning to dutasteride. Nothing was banned or pulled from shelves. What changed is the clarity of the warning about mood and sexual side effects, and what patients are told to do if they experience them.

    If that news has you reconsidering the tablets, this is a genuinely good moment to have a proper conversation with your GP or prescriber about the medicine itself, and separately, to look at what non-drug options such as a hair density consultation can offer. This article covers both, in plain terms, without straying into medical advice we aren't qualified to give.

    What did the MHRA actually announce in May 2026?

    On 11 May 2026, the Medicines and Healthcare products Regulatory Agency published a press release confirming it had issued updated safety advice to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride, and to provide precautionary advice on a related medicine, dutasteride. You can read the full MHRA press release here.

    The update followed what the agency describes as an additional detailed review of the evidence, including the outcome of a European regulatory review conducted under Article 31, alongside expert advice from the Commission on Human Medicines. Dr Alison Cave, the MHRA's Chief Safety Officer, said the agency had strengthened product information for both finasteride 1mg and dutasteride "to provide clearer guidance on these potential risks and to support informed discussions between healthcare professionals and patients." She added that patient safety is the agency's top priority, and that prescribers are expected to discuss the relevant safety information with patients so they can make an informed decision about their own treatment.

    For context on the medicines themselves: finasteride is used at a 1mg dose for male pattern hair loss, and at a 5mg dose for benign prostatic hyperplasia, an enlarged prostate. Dutasteride, at a 0.5mg dose, is used only for prostate conditions, it isn't licensed for hair loss at all. The update covers both drugs because they work in a similar way, even though most of the public conversation has focused on the hair loss use.

    How is this different from the 2024 warning?

    It's worth being precise, because a lot of the coverage circulating online blurs the two updates together.

    Back in 2024, the MHRA completed an earlier safety review into finasteride. That review led to strengthened product warnings and the introduction of UK patient alert cards, which are still in place today and haven't been withdrawn or changed by this latest update. Those cards flag the risks of sexual dysfunction and mood related side effects and set out what a patient should do if they experience them.

    The 2026 update is more specific than that earlier one. According to the full Drug Safety Update published by the MHRA, two things changed:

    • The product information for finasteride 1mg for androgenetic alopecia was updated to clarify that sexual dysfunction may contribute to mood disorders in some patients, and that sexual dysfunction has also been reported without any accompanying mood change. In other words, the two effects can occur together or entirely separately, and the leaflet now says so more clearly.
    • A precautionary warning was added to dutasteride's product information, noting that mood alterations have been reported with finasteride, a medicine in the same pharmacological class. The MHRA is explicit that the evidence specifically involving dutasteride was very limited, and that this addition was made as a precaution rather than because of a wave of new dutasteride reports.

    So the 2024 update told patients and prescribers that these risks existed at all. The 2026 update sharpens the wording around how sexual and psychiatric side effects relate to each other for finasteride, and extends a cautious version of the same warning to dutasteride, largely because the two drugs share a mechanism rather than because of new evidence unique to dutasteride itself.

    Does this mean finasteride has been banned or withdrawn?

    No. Nothing about this update removes finasteride or dutasteride from use in the UK. This is a product information update, meaning the patient leaflet and the technical prescribing information are being rewritten to be clearer, not a recall, a suspension or a change in licensing status.

    The MHRA's own language backs this up. The agency talks about supporting "informed discussions between healthcare professionals and patients," not restricting access to the medicine. Its advice for healthcare professionals is to review a patient's medical record, ask about any personal history of depression or suicidal ideation before prescribing, and review patients regularly for psychiatric or sexual side effects while they're on treatment. That's a call for more careful prescribing and monitoring, not a withdrawal of the drug.

    It's also worth knowing where finasteride sits in the wider picture of hair loss treatment, because that hasn't changed. The NHS is direct about this: finasteride and minoxidil are described as the main treatments for male pattern baldness, but the NHS is equally clear that these treatments do not work for everyone, only work for as long as they continue to be used, and are not all available through the NHS. According to the MHRA, finasteride 1mg for hair loss is only available privately, which is a separate point from the safety update but one that's easy to lose in the headlines.

    What should you do if you're currently taking finasteride or dutasteride?

    We are a hair replacement studio, not a prescriber, and nothing here is medical advice. But it's worth knowing exactly what the MHRA is telling patients to do, in its own words, because that's the information your decision should be based on.

    The Drug Safety Update sets out specific advice for patients already taking either medicine:

    • Read and keep the finasteride patient card and the patient information leaflet that comes in the pack, and tell your doctor if you have any personal history of depression or suicidal thoughts before starting or continuing treatment.
    • If you're taking finasteride 1mg and you develop depression or suicidal thoughts, stop the medicine immediately and contact your doctor as soon as possible.
    • If you're taking finasteride 5mg or dutasteride and you develop depression or suicidal thoughts, contact your doctor as soon as possible.
    • If you experience decreased sex drive, difficulty having an erection, or ejaculation problems while on either medicine, contact your doctor for advice rather than simply stopping or continuing without discussing it.
    • If you have seriously harmed yourself or feel you are at risk of serious harm, contact emergency services on 999 immediately.

    None of that is guidance we've written. It's taken directly from the MHRA's own advice to patients, and it's the right first port of call if any of this applies to you. If you're simply weighing up whether to start or continue finasteride and want to understand your options properly, that conversation belongs with your GP, your prescriber, or a dermatologist, who can look at your specific history and the balance of risks and benefits in a way we're not able to.

    If you're reconsidering medication, what are the non-drug options for thinning hair?

    A lot of men who come to us after reading about this update aren't in crisis, they're simply tired of the tablets, uneasy about the side effect profile, or have decided the daily routine isn't worth it for them personally. That's a completely reasonable position, and it's exactly where non-drug options become relevant.

    The NHS itself notes that these treatments "only work for as long as they're used", which is worth sitting with. Whatever benefit the tablets have given you is tied to continuing them. A hair system, scalp micropigmentation, or a hair density treatment doesn't work that way. There's no daily dose to maintain and nothing pharmacological to weigh up with your GP.

    Broadly, there are three routes people take once medication is off the table, or being scaled back:

    • Hair density treatment, which adds fullness into hair you already have rather than replacing it outright. It suits diffuse thinning where the hair is still present but finer or sparser than it used to be. Our guide to hair density treatment for thinning hair covers who this tends to suit.
    • A custom hair system, which gives an immediate, full result regardless of how advanced the thinning is. Unlike medication, there's no waiting months to see whether it's working, because the result is visible from the day it's fitted. Our guide to non-surgical hair replacement for men in the UK explains how these work day to day.
    • Scalp micropigmentation, which suits men who prefer to keep their hair very short or shaved, and want the appearance of density on a close crop rather than added hair itself.

    If you want a wider comparison of these against surgical options too, our piece on hair transplant alternatives walks through the practical differences without any of the sales pressure that tends to surround this topic online.

    How does a hair density consultation actually work?

    It's a straightforward, unhurried look at your hair and scalp, nothing more. You come in, we look at the pattern of thinning, how much hair you still have to work with, and whether your goals are realistic for that. We won't promise regrowth or a cure, because no honest specialist can, and we won't tell you to abandon a conversation you should be having with your GP.

    What we can tell you is whether hair density treatment is a sensible fit for what we see, whether a hair system would suit you better, or whether it's genuinely too early to tell anything useful. Our page on what happens at a free hair loss consultation sets out exactly what to expect, and our FAQ page answers the practical questions people usually ask before booking.

    The studio itself is private. There's no signage on the door, nothing about your visit is shared with anyone, and the whole point of the appointment is to give you clear information so you can make your own decision, in your own time.

    Book a free confidential consultation

    Book a free confidential consultation at Men's Hair To Stay in Amersham. The studio is private, there is no signage on the door, and nothing you discuss is shared with anyone. Men and women, all hair types and backgrounds welcome.

    We serve Amersham, Chesham, Beaconsfield, High Wycombe, Rickmansworth, Watford, Harrow and across Buckinghamshire and South Bucks.

    Call 07947 878087 or book your free consultation online. Open Tuesday to Friday, 9:30 to 5.

    Sources

    1. MHRA strengthens safety warnings for finasteride and dutasteride - GOV.UKhttps://www.gov.uk/government/news/mhra-strengthens-safety-warnings-for-finasteride-and-dutasteride
    2. Finasteride and Dutasteride, updated safety warnings for psychiatric side effects and sexual dysfunction - GOV.UK Drug Safety Updatehttps://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction
    3. Hair loss - NHShttps://www.nhs.uk/symptoms/hair-loss/

    Get in Touch

    Call or email us and we'll add you to our list for tips, guides and exclusive offers.